UNC Lead Academic Participating Site

北卡罗来纳大学领导学术参与网站

• 批准号: 10582525
• 负责人: LISA A CAREY
• 金额: $ 50.5万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10582525
• 关键词: Applied Research; Award; Cancer Center; Cancer Patient; Caring; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Complement; Comprehensive Cancer Center; DNA; Dedications; Development; Extramural Activities; Faculty; Fostering; Funding; Genome; Goals; Grant; Health; Institution; Investigational Therapies; Investments; Lead; Leadership; Malignant Neoplasms; Medical; Mission; National Clinical Trials Network; North Carolina; Operative Surgical Procedures; Persons; Proteomics; RNA; Radiation; Research; Science; Site; State Hospitals; Technology; Testing; Translational Research; UNC Lineberger Comprehensive Cancer Center; Universities; cancer therapy; cancer type; clinical care; design; feasibility trial; improved; improved outcome; member; multidisciplinary; next generation; operation; programs; success; translational engagement; translational research program

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer patients across this growing state. Ranked “Exceptional” by the NCI at the most recent review in 2015 and with $233M in cancer- related extramural funding, UNC LCCC has an outstanding Clinical/Translational Research Program including a centralized clinical trials office complemented by a highly engaged translational component. This Lead Academic Participating Site (LAPS) application mirrors our clinical research program goal to improve cancer treatment by conducting practice-changing clinical trials and fostering research that will inform the next generation of clinical trials. UNC LCCC’s national stature in clinical research is illustrated by being one of a few centers to receive all three competitive NCI clinical research awards in the last funding cycle (an NCTN LAPS award, a tri-center UM1 grant for participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) and an NCTN Integrated Technology Science Center (ITSC) award). As a National Clinical Trials Network (NCTN) Lead Academic Participating Site, UNC LCCC plans to accomplish the following aims: (1) To provide scientific leadership and intellectual input into the creation of thoughtful, feasible trials to improve the health of cancer patients; (2) To support NCTN trials with robust accrual through our growing clinical enterprise; and (3) To provide opportunities for excellent translational science embedded into and informing NCTN trials.

UNC Lineberger综合癌症中心（UNC LCCC）试图继续担任主要学术 国家临床试验网络（NCTN）的参与地点。 UNC LCCC是唯一的公共NCI指定 北卡罗来纳州的综合癌症中心，致力于改善此处的癌症患者的结局 增长状态。 NCI在2015年的最新评论中排名为“异常”，癌症为2.33亿美元 相关的壁外资金，UNC LCCC拥有出色的临床/转化研究计划 集中式临床试验办公室由高度参与的翻译组件完成。这是领导学者 参与地点（LAPS）应用程序反映了我们的临床研究计划目标，以改善通过 进行改变实践的临床试验并促进研究，以告知下一代临床 试验。 UNC LCCC在临床研究方面的国家地位是获得全部的几个中心之一 上一个融资周期中的三项竞争性NCI临床研究奖（NCTN圈奖，三中心UM1 参与实验治疗学临床试验网络（ETCTN）和NCTN集成的授予 技术科学中心（ITSC）奖）。作为国家临床试验网络（NCTN）领导学术 参与网站，UNC LCCC计划实现以下目的：（1）提供科学领导和 智力投入到创建周到，可行的试验以改善癌症患者的健康状况； （2）至 通过我们不断增长的临床企业来支持NCTN试验； （3）提供机会 对于出色的转化科学，嵌入并告知了NCTN试验。